TORL Looks To Break Ground In Growing Field Of Claudin-Targeting Drugs

TORL BioTherapeutics LLC is aiming for its latest fundraise to take it past the regulatory finish line with TORL-1-23, which it calls a first-in-class antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6) in platinum-resistant ovarian cancer. TORL-1-23 is part of a suite of ADCs it is developing for solid tumors, including one against Claudin 18.2 (CLDN18.2), the target of a recently approved Astellas Pharma, Inc. drug and a growing number of therapeutic candidates that include cell therapies.

TORL said 10 April that it closed an oversubscribed series B-2 venture capital financing of $158m, led by Deep Track...